Tregs characterized by the expression of the master transcription factor FOXP3 suppress anticancer immunity, thereby hindering protective immunosurveillance of tumors and hampering effective antitumor immune responses in tumor-bearing hosts, constitute a current research hotspot in the field51. This evidence concerns the gene FOXP3 and neoplasm.